· Pharma · Pharma Desk
With the FDA formally ending the GLP-1 shortage, Hims & Hers is pivoting from compounded semaglutide/tirzepatide to branded LillyDirect and Novo channels — a live case study in how a single regulatory ruling rewrites peptide economics overnight.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.